NeoGenomics Announces Senior Leadership Promotions

Download as PDF

FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately.

Warren Stone has been promoted to Chief Commercial Officer and will lead NeoGenomics’ clinical and pharma services commercial teams. Stone will be responsible for sales, marketing, pharma project management, commercial enablement, scientific affairs, and support functions.

Melody Harris has been promoted to Chief Operations Officer and President, Informatics. In this expanded role, Harris will oversee data-oriented teams and manage all enterprise operations.

“Warren and Melody have shown exceptional leadership and performance in their respective roles," said Chris Smith, CEO of NeoGenomics. “As we enter our next phase of growth, these senior leadership appointments should drive operational efficiencies, strengthen commercial synergies, and accelerate innovation through R&D. We believe their extensive experience will enhance the operating structure of the organization, thereby improving our service to clinicians and patients.”

Stone joined NeoGenomics in 2022 as President of Clinical Services. He has played a leading role in optimizing NeoGenomics’ salesforce and successfully implementing its commercial strategy and digital transformation of systems and tools. Prior to NeoGenomics, Stone served as President of Americas at Ortho Clinical Diagnostics and Senior Vice President, Life Sciences Division for MilliporeSigma. He holds an MBA from Suffolk University.

Harris joined NeoGenomics in 2022 as President of Enterprise Operations. She has led the company through a laboratory transformation including improvements in turnaround time and currently manages the consolidation of several laboratory information management systems (LIMS) into a single system. Prior to NeoGenomics, Harris served as President and Chief Operating Officer at SomaLogic and held several executive positions at Qualcomm Life’s digital health subsidiary and at HealthyCircles, a healthcare web platform. Harris holds a BA, cum laude, in Political Science from the University of Denver and a JD, cum laude, from Harvard Law School.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, Fla., NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Investor Contact
Kendra Sweeney
kendra.sweeney@neogenomics.com

Media Contact
Andrea Sampson
asampson@sampsonprgroup.com

Source: NeoGenomics, Inc.

Released April 18, 2024